(QGEN) Qiagen - Overview

Exchange: NYSE • Country: Netherlands • Currency: USD • Type: Common Stock • ISIN: NL0015002CX3

Stock:

Total Rating 65

Risk 92

Buy Signal 0.13

Diagnostics & Research -12.9
Life Sciences Tools & Services -15.0

Market Cap: 10,019m
Avg Trading Vol: 96.6M USD

ATR: 2.56%
Peers RS (IBD): 74.07

Risk 5d forecast
Volatility	24.2%
Relative Tail Risk	-7.74%

Reward TTM
Sharpe Ratio	1.05
Alpha	23.01

Character TTM
Beta	0.603
Beta Downside	0.173

Drawdowns 3y
Max DD	24.75%
CAGR/Max DD	0.22

EPS (Earnings per Share)

EPS CAGR: -14.71%
EPS Trend: -12.0%

Last SUE: -0.20
Qual. Beats: 0

Revenue

Rev. CAGR: -3.94%
Rev. Trend: -7.4%

Last SUE: 3.22
Qual. Beats: 4

Description: QGEN Qiagen

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, such as assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables, such as short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments; bioinformatics solutions; and custom laboratory and genomic services. The company provides software-as-a-service. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Piotroski VR‑10 (Strict, 0-10) 6.5

Net Income: 424.9m TTM > 0 and > 6% of Revenue
FCF/TA: 0.07 > 0.02 and ΔFCF/TA -1.64 > 1.0
NWC/Revenue: 70.95% < 20% (prev 71.59%; Δ -0.64% < -1%)
CFO/TA 0.10 > 3% & CFO 654.3m > Net Income 424.9m
Net Debt (815.4m) to EBITDA (717.3m): 1.14 < 3
Current Ratio: 3.90 > 1.5 & < 3
Outstanding Shares: last quarter (207.8m) vs 12m ago -4.70% < -2%
Gross Margin: 61.79% > 18% (prev 0.49%; Δ 6131 % > 0.5%)
Asset Turnover: 34.88% > 50% (prev 34.77%; Δ 0.11% > 0%)
Interest Coverage Ratio: 15.74 > 6 (EBITDA TTM 717.3m / Interest Expense TTM 33.3m)

Altman Z'' 4.55

A: 0.24 (Total Current Assets 2.00b - Total Current Liabilities 512.1m) / Total Assets 6.30b
B: 0.44 (Retained Earnings 2.75b / Total Assets 6.30b)
C: 0.09 (EBIT TTM 523.5m / Avg Total Assets 5.99b)
D: 0.94 (Book Value of Equity 2.37b / Total Liabilities 2.52b)
Altman-Z'' Score: 4.55 = AA

Beneish M -3.34

DSRI: 0.83 (Receivables 402.6m/459.0m, Revenue 2.09b/1.98b)
GMI: 0.79 (GM 61.79% / 48.90%)
AQI: 1.03 (AQ_t 0.54 / AQ_t-1 0.52)
SGI: 1.06 (Revenue 2.09b / 1.98b)
TATA: -0.04 (NI 424.9m - CFO 654.3m) / TA 6.30b)
Beneish M-Score: -3.34 (Cap -4..+1) = AA

What is the price of QGEN shares?

As of March 02, 2026, the stock is trading at USD 49.80 with a total of 1,271,866 shares traded.
Over the past week, the price has changed by +4.95%, over one month by -4.56%, over three months by +10.84% and over the past year by +38.01%.

Is QGEN a buy, sell or hold?

Qiagen has received a consensus analysts rating of 3.94. Therefore, it is recommended to buy QGEN.

StrongBuy: 6
Buy: 3
Hold: 7
Sell: 0
StrongSell: 0

What are the forecasts/targets for the QGEN price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	55.2	10.9%
Analysts Target Price	55.2	10.9%

QGEN Fundamental Data Overview February 27, 2026

P/E Trailing = 23.8333
P/E Forward = 16.9492
P/S = 4.794
P/B = 2.8602
P/EG = 0.32
Revenue TTM = 2.09b USD
EBIT TTM = 523.5m USD
EBITDA TTM = 717.3m USD
Long Term Debt = 1.63b USD (from longTermDebt, two quarters ago)
Short Term Debt = 499.6m USD (from shortTermDebt, two quarters ago)
Debt = 1.65b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 815.4m USD (from netDebt column, last quarter)
Enterprise Value = 10.57b USD (10.02b + Debt 1.65b - CCE 1.10b)
Interest Coverage Ratio = 15.74 (Ebit TTM 523.5m / Interest Expense TTM 33.3m)
EV/FCF = 23.36x (Enterprise Value 10.57b / FCF TTM 452.6m)
FCF Yield = 4.28% (FCF TTM 452.6m / Enterprise Value 10.57b)
FCF Margin = 21.66% (FCF TTM 452.6m / Revenue TTM 2.09b)
Net Margin = 20.33% (Net Income TTM 424.9m / Revenue TTM 2.09b)
Gross Margin = 61.79% ((Revenue TTM 2.09b - Cost of Revenue TTM 798.5m) / Revenue TTM)
Gross Margin QoQ = 58.71% (prev 62.20%)
Tobins Q-Ratio = 1.68 (Enterprise Value 10.57b / Total Assets 6.30b)
Interest Expense / Debt = 0.61% (Interest Expense 10.1m / Debt 1.65b)
Taxrate = 1.23% (1.34m / 109.2m)
NOPAT = 517.1m (EBIT 523.5m * (1 - 1.23%))
Current Ratio = 3.90 (Total Current Assets 2.00b / Total Current Liabilities 512.1m)
Debt / Equity = 0.44 (Debt 1.65b / totalStockholderEquity, last quarter 3.78b)
Debt / EBITDA = 1.14 (Net Debt 815.4m / EBITDA 717.3m)
Debt / FCF = 1.80 (Net Debt 815.4m / FCF TTM 452.6m)
Total Stockholder Equity = 3.59b (last 4 quarters mean from totalStockholderEquity)
RoA = 7.09% (Net Income 424.9m / Total Assets 6.30b)
RoE = 11.85% (Net Income TTM 424.9m / Total Stockholder Equity 3.59b)
RoCE = 10.04% (EBIT 523.5m / Capital Employed (Equity 3.59b + L.T.Debt 1.63b))
RoIC = 9.98% (NOPAT 517.1m / Invested Capital 5.18b)
WACC = 7.07% (E(10.02b)/V(11.67b) * Re(8.14%) + D(1.65b)/V(11.67b) * Rd(0.61%) * (1-Tc(0.01)))
Discount Rate = 8.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.65%
[DCF] Terminal Value 81.35% ; FCFF base≈472.5m ; Y1≈462.8m ; Y5≈470.0m
[DCF] Fair Price = 45.20 (EV 10.13b - Net Debt 815.4m = Equity 9.31b / Shares 206.0m; r=7.07% [WACC]; 5y FCF grow -3.02% → 2.90% )
EPS Correlation: -11.96 | EPS CAGR: -14.71% | SUE: -0.20 | # QB: 0
Revenue Correlation: -7.44 | Revenue CAGR: -3.94% | SUE: 3.22 | # QB: 4
EPS next Quarter (2026-06-30): EPS=0.62 | Chg7d=-0.000 | Chg30d=-0.056 | Revisions Net=-6 | Analysts=11
EPS current Year (2026-12-31): EPS=2.51 | Chg7d=+0.001 | Chg30d=-0.178 | Revisions Net=-11 | Growth EPS=+5.5% | Growth Revenue=+6.1%
EPS next Year (2027-12-31): EPS=2.80 | Chg7d=-0.003 | Chg30d=-0.136 | Revisions Net=-6 | Growth EPS=+11.5% | Growth Revenue=+5.9%
[Analyst] Revisions Ratio: -1.00 (0 Up / 6 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.9% (Discount Rate 8.1% - Earnings Yield 4.2%)
[Growth] Growth Spread = +0.1% (Analyst 4.0% - Implied 3.9%)

Additional Sources for QGEN Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle